首页 | 本学科首页   官方微博 | 高级检索  
     

LGT不同表达对结直肠癌术后FOLFOX方案巩固化疗的远期生存的分析
引用本文:张静,裴毅. LGT不同表达对结直肠癌术后FOLFOX方案巩固化疗的远期生存的分析[J]. 现代保健, 2012, 0(23): 6-8
作者姓名:张静  裴毅
作者单位:[1]山西医科大学,山西太原030001 [2]山西省肿瘤医院,山西太原030001
摘    要:目的:探讨LGT 不同表达对结直肠腺癌患者手术后应用FOLFOX 方案巩固治疗后远期生存的影响.方法:选取2006 年1 月-2009年1 月首次入院并行手术治疗的结直肠腺癌患者55 例,手术前行SELDI 检测,留取指纹图.术后给予标准FOLFOX 方案巩固化疗4~6 周期.随访至2011 年8 月.观察2010 年至今,不同年龄、性别,LGT 表达与否条件下,无疾病进展生存期和中位生存期两组的差异.结果:年龄以65 岁分组,两者在无疾病进展生存期和中位生存期上比较差异均无统计学意义(7.85:6.50,P=0.770 ;15.75:13.00,P=0.517).按性别分组,男女在无疾病进展生存期和中位生存期上比较差异均无统计学意义(8.50:4.95,P=0.152 ;17.00:10.00,P=0.203).LGT 阳性者,无疾病进展中位生存期为2.8 个月,LGT 阴性者,无疾病进展中位生存期为10 个月,差异有统计学意义(P=0.000).LGT 阳性者,中位生存期为5.85 个月,LGT 阴性者,中位生存期为18.5 个月,差异有统计学意义(P=0.000).结论:手术前LGT 表达组无疾病进展及中位生存期远低于LGT 阴性组.建议手术前如LGT 为阳性表达,首先控制LGT,待LGT 表达正常后再行手术,以确保治疗后效果.

关 键 词:结直肠癌  巩固化疗  危重病人预警蛋白质  预后

Analysis of LGT Different Expression and Long-term Survival Using FOLFOX Chemotherapy after Colorectal Cancer Surgery
ZHANG Jing,PEI Yi. Analysis of LGT Different Expression and Long-term Survival Using FOLFOX Chemotherapy after Colorectal Cancer Surgery[J]. , 2012, 0(23): 6-8
Authors:ZHANG Jing  PEI Yi
Affiliation:( Shanxi Medical University, Taiyuan 030001, China)
Abstract:Objective: To study the different expression of LGT and Long-term survival of FOLFOX chemotherapy after colorectal cancer surgery. Method: Choose 55 patients use surgical treatment of parallel colorectal, between January 2006 to January 2009.All the patient detect SELDI to get the map of fingerprint , use four to six cycles of FOLFOX chemotherapy, follow-up to August 2011. A different age, gender, LGT express or not, under the conditions of disease progression of survival and without a median of two groups of the differences. Result:In the absence of survival and disease progression median survival were no significant difference (7.85, 6.50, P=0.770;15.75:13.00, P=0.517)between ≥ 65 years old group and〈 65 years old group;There is no significant difference among the men and women group (8.50, 4.95, P=2.057;17.00:10.00, P=l.622).No disease progress for a median is 2.8 months in LGT positive patient, 10 months in LGT negative patient(P=O.OOO).Progress for a median is 5.85 months in LGT positive patient, 18.5 months in LGT negative patient(P=0.000).Conclusion:Both the no disease progress for a median and progress for a median in LGT positive group is far lower than the LGT negative group.Before the operation such as LGT positive for express, first control LGT, LGT expression to normal after poste ooeration, to ensure that the treatment effect.
Keywords:Colorectal cancer  Consolidate chemotherapy  LGT  Prognosis
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号